NASDAQ · Biotechnology

ZNTL (ZNTL) Stock

$4.74 -3.66% NASDAQ: ZNTL Healthcare

Valuation

MetricValue
Price$4.74
Market Cap$337.42M
P/E Ratio-1.86
P/B Ratio1.17
P/S Ratio0.00
EPS (TTM)$-1.91
52-Week High$6.95
52-Week Low$1.13
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-63.43%
ROA-47.40%
ROCE-70.83%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.19
Current Ratio6.84

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$67.0M$0
Operating Profit$-217.0M$-227.0M$-300.0M$-191.0M$-153.0M
Net Profit$-159.0M$-237.0M$-292.0M$-166.0M$-137.0M
EPS$-3.72$-4.48$-4.47$-2.33$-1.91
Op Margin———-283.6%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$472.0M$553.0M$562.0M$430.0M$289.0M
Total Liabilities$108.0M$119.0M$125.0M$93.0M$73.0M
Cash$60.0M$43.0M$28.0M$34.0M$36.0M
Borrowings$46.0M$47.0M$46.0M$43.0M$40.0M

Latest News

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? Zacks · Jul 20, 2026 Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 GlobeNewswire · Jul 17, 2026 Zentalis Shares Rise After Mizuho Initiates Coverage at Outperform MT Newswires · Jul 17, 2026 Mizuho Initiates Zentalis Pharmaceuticals at Outperform With $8 Price Target MT Newswires · Jul 17, 2026 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-154.0M$-164.0M$-208.0M$-171.0M$-125.0M
Investing Cash Flow$-24.0M$-117.0M$-45.0M$176.0M$132.0M
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$6.0M$-17.0M$-15.0M$6.0M$2.0M
Free Cash Flow$-160.0M$-166.0M$-208.0M$-171.0M$-125.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-47.56%
Quick Ratio6.19
Interest Coverage—
Return 1Y194.70%
Return 3Y-82.67%
Return 5Y-89.91%

Ownership

Insiders Held22.84%
Institutions Held61.89%
Institutions Float Held80.21%
Institutional HolderSharesReport Date
5AM Venture Management, LLC3,947,9132026-03-31
Squadron Capital Management LLC3,631,0002026-03-31
Two Sigma Investments, LP2,956,5262026-03-31
Acadian Asset Management. LLC2,848,2522026-03-31
Vanguard Capital Management LLC2,310,7072026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALXO $1.95 -2.26% -1.04 $261.72M 0.00%
ARTV $11.27 -2.68% -2.29 $278.56M 0.00%
DTIL $7.00 +1.60% -1.97 $89.80M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%
MGNX $3.78 +3.00% -2.92 $240.27M 0.00%

About ZNTL

ZNTL is led by CEO Julie Eastland, employs 166 people, headquartered in US, publicly traded since 2020.

ZNTL stock trades at $4.74 with a market capitalization of $337.42M. The stock is valued at a price-to-earnings (P/E) ratio of -1.86, price-to-book of 1.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.13 and $6.95, and currently trades 31.8% below its 52-week high.

On profitability, ZNTL generates a return on equity (ROE) of -63.43%, return on capital employed of -70.83%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides